{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-034740","form_type":"8-K","ticker":"AIM","cik":"0000946644","company_name":"AIM ImmunoTech Inc.","filed_at":"2023-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.110028+00:00","generated_at":"2026-06-10T07:20:00.829173+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"AIM ImmunoTech enters amended research agreement with Roswell Park for Ampligen® studies","bullets":["Agreement covers three clinical trials: melanoma, prostate cancer, triple-negative breast cancer.","AIM will supply Ampligen® to Roswell Park for research projects at no cost.","Term is three years from September 20, 2023, or until completion of research.","Research may be funded by external entities (NIH, DOD, foundations); no financial terms disclosed.","AIM retains ownership of Ampligen® and pre-existing IP; jointly developed inventions are shared."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-034740","json":"https://secwatch.observer/filing/0001493152-23-034740.json","markdown":"https://secwatch.observer/filing/0001493152-23-034740.md","text":"https://secwatch.observer/filing/0001493152-23-034740.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946644/000149315223034740/0001493152-23-034740-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946644/000149315223034740/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T07:20:00.829173+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"72a1aafe45dc2c5f9bb00a4d7ee29c88173a6f9b","claim":"AIM ImmunoTech Inc. entered into Amended and Restated Material Transfer and Research Agreement with Roswell Park Cancer Institute Corporation d/b/a Roswell Park Comprehensive Cancer Center (effective 2023-09-28).","evidence_excerpt":"On September 28, 2023, AIM ImmunoTech Inc. (the “Company”) executed an Amended and Restated Material Transfer and Research Agreement (the “Agreement”) with Roswell Park Cancer Institute Corporation d/b/a Roswell Park Comprehensive Cancer Center (“Roswell”) that amends and restates the prior related agreements.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/946644/000149315223034740/0001493152-23-034740-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Roswell Park Cancer Institute Corporation d/b/a Roswell Park Comprehensive Cancer Center"},{"label":"Effective","value":"2023-09-28"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}